26 U.S.C. 5000D(d)26 U.S.C. 5000DUnited States Code, Cornell LII. The percentage is tax divided by (tax plus price), so the tax is a multiple of the price, not a share of it.
What the tax is
Section 5000D is an excise tax that backs the Medicare drug price negotiation program created by the Inflation Reduction Act of 2022. It is imposed “on the sale by the manufacturer, producer, or importer of any designated drug during a day described in subsection (b)” (IRC 5000D(a)). The days in subsection (b) are noncompliance periods: times when the manufacturer has not signed the program agreement, has not agreed to a negotiated price, or is late with information the program requires. It applies to sales after Aug. 16, 2022.
A designated drug is “any negotiation-eligible drug (as defined in section 1192(d) of the Social Security Act) included on the list published under section 1192(a) of such Act which is manufactured or produced in the United States or entered into the United States for consumption, use, or warehousing” (IRC 5000D(e)(1))IRC 5000DInternal Revenue Code, Cornell LII. It is reported on Form 720 in Part II as IRS No. 142:
| IRS No. | Rate | Period | Authority |
|---|---|---|---|
| 142 | Applicable percentage of 65% to 95% (the tax is set so this percentage is met, by days in the statutory period) | Quarters beginning on or after Oct. 1, 2023 (return rule) | IRC 5000D(d)IRC 5000DInternal Revenue Code, Cornell LII; 26 CFR 40.6011(a)-1 |
How the tax is figured
The tax is not a percentage of the price in the usual sense. The statute sets the tax “in an amount such that the applicable percentage is equal to the ratio of” the tax to the sum of the tax and the price (IRC 5000D(a)). The applicable percentage rises with the days in the period: “in the case of sales of a designated drug during the first 90 days described in subsection (b) with respect to such drug, 65 percent,” then 75 percent for days 91 to 180, 85 percent for days 181 to 270, and “in the case of sales of such drug during any subsequent day, 95 percent.” (IRC 5000D(d))IRC 5000DInternal Revenue Code, Cornell LII.
Solved for the tax, that means the tax is the price times p divided by (1 minus p). At 65 percent the tax is about 1.86 times the price; at 95 percent it is 19 times the price. Notice 2023-52 gives the IRS's own example where no separate charge is made: “if a manufacturer charges a purchaser $100 for a designated drug during the first 90 days in a statutory period and does not make a separate charge for the § 5000D tax, $65 is allocated to the § 5000D tax and $35 is allocated to the price of the designated drug”.
26 U.S.C. 5000D(a)26 U.S.C. 5000DUnited States Code, Cornell LII and (d). Multiples computed from the statute: tax = price x p / (1 - p), rounded.
Two special rules in the statute: exports are handled under rules like those for the Superfund chemical taxes (IRC 5000D(g)IRC 5000DInternal Revenue Code, Cornell LII, referring to 4662(e)), and “In the case of a sale which was timed for the purpose of avoiding the tax imposed by this section, the Secretary may treat such sale as occurring during a day described in subsection (b).” (IRC 5000D(f)(2))IRC 5000DInternal Revenue Code, Cornell LII.
When the tax applies
IRC 5000D(b)IRC 5000DInternal Revenue Code, Cornell LII lists four kinds of noncompliance period for a drug on the Medicare negotiation list:
- No agreement. From the March 1 after the drug is listed (October 2 for initial price applicability year 2026) until the manufacturer has an agreement in place or the Secretary of Health and Human Services makes a determination under section 1192(c)(1) of the Social Security Act for the drug.
- No agreed price. From the November 2 after that March 1 (August 2 for 2026) until the manufacturer and the Secretary agree to a maximum fair price, or that determination is made.
- Renegotiation. For a drug selected for renegotiation, from the November 2 set by the statute until a renegotiated price is agreed, or that determination is made.
- Overdue information. From the date the Secretary certifies that information the agreement requires is overdue “and ending on the date that such information is so submitted”.
Days are suspended while a manufacturer has terminated all of its Medicare discount and Medicaid rebate agreements and none of its drugs is covered, until the end of February after it rejoins (IRC 5000D(c))IRC 5000DInternal Revenue Code, Cornell LII. A manufacturer in the program, on time with its agreement, price and information, has no days in a period and no tax.
Notice 2023-52 and the regulations
Notice 2023-52 (2023), guidance a taxpayer may rely on. The notice announced that Treasury and the IRS “intend to propose regulations (forthcoming proposed regulations) addressing § 5000D of the Internal Revenue Code” (Notice 2023-52). It said the tax would reach “taxpayer sales of designated drugs dispensed, furnished, or administered to individuals under the terms of Medicare”, that a tax separately charged on the invoice is not part of the price, and that the Form 720 procedures would apply with no semimonthly deposits. “Until the Treasury Department and the IRS issue further guidance, taxpayers may rely on section 3 of this notice.”
Final procedural regulations (T.D. 10003, July 5, 2024). The return rules in the notice became final in 26 CFR part 4026 CFR part 40Code of Federal Regulations, eCFR: “A return that reports liability imposed by section 5000D of the Internal Revenue Code must be made for a period of one calendar quarter.” “There is no requirement that a return be filed for a calendar quarter in which there is no liability imposed by section 5000D.” The rule “applies to returns filed for calendar quarters beginning on and after October 1, 2023.” (26 CFR 40.6011(a)-1(d) and (e)(3)). Section 5000D is also on the regulation's list of taxes with no deposits (26 CFR 40.6302(c)-1(e)).
Rules on what is taxed and how to compute it. The scope and computation rules the notice described were to come as proposed regulations. The saved IRS sources (the Form 720 instructions of June 2026, the eCFR text as of November 2026 and the IRS manuals) show no proposed or final regulations on them, so section 3 of Notice 2023-52 remains the guidance to rely on. The notice also said “The IRS also intends to issue a new form that taxpayers would be required to attach to Form 720 to compute any § 5000D tax liability”; the IRS processing manual lists a Form 7209, “Excise Tax on Sales of Designated Drugs During Statutory Periods (may be attached to Form 720)”, but no Form 7209 was found on irs.gov's forms pages on Nov. 22, 2026.
Filing on Form 720
26 CFR 40.6011(a)-1(d) and 40.6302(c)-1(e) (T.D. 10003, July 5, 2024); Instructions for Form 720 (Rev. June 2026).
The Form 720 instructions say: “Under Regulations section 40.6011(a)-1, taxpayers are required to report any section 5000D drug tax liability on Form 720.” The return for a quarter with liability is due by the last day of the month after the quarter (April 30, July 31, October 31 or January 31), and the tax is paid with it: Notice 2023-52 said the payment deadline would be “the same as the filing deadline for Form 720”. “If any due date for filing a return falls on a Saturday, Sunday, or legal holiday, you may file the return on the next business day.”
A manufacturer that files Form 720 only for this tax does not file in quarters without liability. One that files Form 720 for other taxes reports IRS No. 142 on its regular return. Changes go on Form 720-X: “You may be required to file Form 720-X to report revisions to previously reported section 5000D liabilities.” The IRS processing manual says IRS No. 142 “is valid for tax periods 202403 and later” (IRM 3.11.23), (tax period 202403 is the quarter ending March 2024).
Like the other Part II taxes this one is paid with the return through EFTPS or a check with Form 720-V. The Form 720 penalties guide covers late filing and late payment.
Questions filers ask
What is the section 5000D excise tax?
A federal excise tax on a manufacturer's, producer's or importer's sales of a drug on the Medicare negotiation list during a noncompliance period, such as a period without a signed agreement or an agreed price. It is reported on Form 720 as IRS No. 142.
How high is the section 5000D tax?
The applicable percentage runs from 65 to 95 percent of the sum of the tax and the price, by days in the period. Solved for the tax, that is about 1.86 times the price at 65 percent and 19 times the price at 95 percent.
Do drug makers file Form 720 every quarter for section 5000D?
No. A return is required for each quarter in which section 5000D liability is incurred, and none is required for a quarter with no liability (26 CFR 40.6011(a)-1(d)).
Are section 5000D deposits required?
No. Section 5000D is on the regulation's list of taxes with no semimonthly deposits; the tax is paid with the quarterly return.
Are there final regulations on how the tax is computed?
Not in the IRS sources as of November 2026. The return and deposit rules are final (T.D. 10003, July 5, 2024); for scope and computation, taxpayers may rely on section 3 of Notice 2023-52 until further guidance.